Combination of L-Carnitine and Angiotensin-II type 1 Receptor Blocker has Beneficial Effects on Hepatic Fibrosis in a Non-Alcoholic Steatohepatitis Rat Model.

• 資料種別: 博士論文
• タイトル: Combination of L-Carnitine and Angiotensin-II type 1 Receptor Blocker has Beneficial Effects on Hepatic Fibrosis in a Non-Alcoholic Steatohepatitis Rat Model.
• 著者・編者: Kubo, Takuya; Kawaratani, Hideto; Sawada, Yasuhiko; Fujinaga, Yukihisa; Ozutsumi, Takahiro; Kaya, Daisuke; Tsuji, Yuki; Nakanishi, Keisuke; Furukawa, Masanori; Kitagawa, Kou; Saikawa, Soichiro; Sato, Shinya; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
• 著者標目: Kubo, Takuya; Kawaratani, Hideto; Sawada, Yasuhiko; Fujinaga, Yukihisa; Ozutsumi, Takahiro; Kaya, Daisuke; Tsuji, Yuki; Nakanishi, Keisuke; Furukawa, Masanori; Kitagawa, Kou; Saikawa, Soichiro; Sato, Shinya; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
• 出版事項: Biomedical Research Network+
• 出版年月日等: 2019-12
• 出版年（W3CDTF）: 2019-12
• 並列タイトル等: L-カルニチンとアンギオテンシン-II1型受容体遮断薬の組み合わせは、非アルコール性脂肪肝炎ラットモデルにおける肝線維症に有益な効果を有する
• タイトル（掲載誌）: Biomedical journal of scientific and technical research
• 巻号年月日等（掲載誌）: 23 5
• 掲載巻: 23
• 掲載号: 5
• 掲載ページ: 17787-17792
• ISSN（掲載誌）: ISSN : 2574-1241
• 授与機関名: 奈良県立医科大学
• 授与年月日: 2020-03-16
• 報告番号: 甲第736号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: Angiotensin-2 type 1 Receptor Blocker; L-carnitine; Nonalcoholic Steatohepatitis; Hepatic Fibrosis; Oxidative Stress
• 対象利用者: 一般
• 一般注記: type:Thesis; Inflammation and oxidative stress contribute to the progression of nonalcoholic steatohepatitis (NASH). Hepatic fibrosis and activated hepatic stellate cells (Ac-HSCs) are attenuated by Angiotensin-II type 1 Receptor Blocker (ARB), and L-carnitine is effective for NASH by ameliorating oxidative stress, but neither agent is effective in a clinical setting. We evaluated the effect of the combination of L-carnitine and ARB on liver fibrosis using a rat NASH model. A Choline-Deficient/L-Amino Acid-defined (CDAA) diet was fed to F344 rats for 8 weeks. The rats were then divided into a control group, group receiving L-carnitine or ARB alone, and group receiving L-carnitine plus ARB. Therapeutic efficacy was assessed by evaluating liver fibrosis, liver fatty acid metabolism, and oxidative stress. ARB inhibited liver-specific tumor necrotic factor-α and LPS-binding protein, which are involved in hepatic inflammation. L-Carnitine reduced hepatic oxidative stress by rescuing hepatic sterol-regulatory elementbinding protein 1 and thiobarbituric acid reactive substances induced by the CDAA diet. Combination of L-carnitine and ARB improved liver fibrosis, with concomitant HSC suppression. Therefore, we suggest that L-carnitine and ARB are effective in suppressing liver fibrosis. Currently both drugs are in clinical use, and a combination of the two could be an effective therapy for NASH fibrosis.; 博士（医学）・甲第736号・令和2年3月16日; Copyright © 2019 Hideto Kawaratani, Biomed J Sci & Tech Res. This is an openaccess article distributed under the terms of the Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/).; identifier:Biomedical journal of scientific and technical research Vol.23 No.5 p.17787-17792 (2019 Dec); identifier:25741241; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3727; identifier:Biomedical journal of scientific and technical research, 23(5): 17787-17792
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.26717/BJSTR.2019.23.003969
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

目次

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3727/1/01%e7%94%b2736%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3727/2/02%e7%94%b2736%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3727/3/03%e7%94%b2736%e6%9c%ac%e6%96%87.pdf fulltext